Piga A, Ambrosetti A, Todeschini G, Cetto G, Perona G, Cellerino R
Cancer Treat Rep. 1984 Jul-Aug;68(7-8):947-51.
Thirty-nine patients with advanced Hodgkin's disease were treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Thirty-one of these patients had previously failed to respond to MOPP (mechlorethamine, vincristine, prednisone, and procarbazine) treatment (29 patients) or to CCVPP (lomustine, cyclophosphamide, vincristine, procarbazine, and prednisone) treatment (two patients). Twenty-seven patients were considered evaluable: eight (30%) achieved complete remission (CR), two (7%) achieved partial remission (PR), and 17 (63%) had no response. All of the complete responders are still in continuous unmaintained CR, while 14 of the 19 partial responders and nonresponders have died. The overall median survival was 21 months; it was 16 months for partial responders and nonresponders. The remaining eight patients had ABVD substituted to MOPP early in treatment, because of allergy to procarbazine: six patients achieved CR and two achieved PR. Our results are in keeping with the literature data and confirm the effectiveness of ABVD as primary and salvage treatment in advanced Hodgkin's disease.
三十九例晚期霍奇金病患者接受了阿霉素、博来霉素、长春花碱和达卡巴嗪（ABVD）治疗。其中31例患者先前对MOPP（氮芥、长春新碱、泼尼松和丙卡巴肼）治疗（29例患者）或CCVPP（洛莫司汀、环磷酰胺、长春新碱、丙卡巴肼和泼尼松）治疗（2例患者）无反应。27例患者被认为可评估：8例（30%）达到完全缓解（CR），2例（7%）达到部分缓解（PR），17例（63%）无反应。所有完全缓解者仍处于持续未维持的CR状态，而19例部分缓解者和无反应者中有14例死亡。总体中位生存期为21个月；部分缓解者和无反应者为16个月。其余8例患者因对丙卡巴肼过敏，在治疗早期用ABVD替代了MOPP：6例患者达到CR，2例达到PR。我们的结果与文献数据一致，并证实了ABVD作为晚期霍奇金病的一线和挽救治疗的有效性。
